Cygnus' GlucoWatch
This article was originally published in The Gray Sheet
Executive Summary
FDA grants expedited review status for the wrist-worn, non-invasive continuous blood glucose monitor, the company announces July 20. Cygnus submitted the final module of a modular premarket approval application on June 1 (1"The Gray Sheet" June 7, p. 12). Expedited review status could bring the PMA before the agency's Clinical Chemistry and Clinical Toxicology Devices Panel at its next meeting, scheduled for Sept. 23-24